Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study

被引：102

作者：

Atzeni, F

Sarzi-Puttini, P

Dell'Acqua, D

de Portu, S

Cecchini, G

Cruini, C

Carrabba, M

Meroni, PL

机构：

[1] L Sacco Univ Hosp, Dept Med, Rheumatol Unit, I-20157 Milan, Italy

[2] Univ Naples Federico II, Fac Pharm, CIRF, Ctr Pharmacoecon, Naples, Italy

[3] Univ Milan, Dept Internal Med, Clin Immunol & Rheumatol Unit, IRCCS,Ist Auxolog Italiano, Milan, Italy

来源：

ARTHRITIS RESEARCH & THERAPY | 2006年 / 8卷 / 01期

关键词：

D O I：

10.1186/ar1851

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Studies on autoantibody production in patients treated with tumor necrosis factor-alpha (TNF-alpha) inhibitors reported contradictory results. We investigated in a prospective study the efficacy of a treatment with human monoclonal anti-TNF-alpha antibody (adalimumab) in patients with rheumatoid arthritis ( RA) and we evaluated the relationship between treatment efficacy and the incidence and titers of disease-associated and non-organ-specific autoantibodies. Fifty-seven patients with RA not responsive to methotrexate and treated with adalimumab were enrolled. Antinuclear, anti-double-stranded(ds)DNA, anti-extractable nuclear antigens, anti-cardiolipin (aCL), anti-beta(2) glycoprotein I (anti-beta(2)GPI) autoantibodies, rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) autoantibodies were investigated at baseline and after 6 and 12 months of follow-up. Comparable parameters were evaluated in a further 55 patients treated with methotrexate only. Treatment with adalimumab induced a significant decrease in RF and anti-CCP serum levels, and the decrease in antibody titers correlated with the clinical response to the therapy. A significant induction of antinuclear autoantibodies ( ANA) and IgG/IgM anti-dsDNA autoantibodies were also found in 28% and 14.6% patients, respectively, whereas aCL and anti-beta(2)GPI autoantibodies were not detected in significant quantities. No association between ANA, anti-dsDNA, aCL and anti-beta(2)GPI autoantibodies and clinical manifestations was found. Clinical efficacy of adalimumab is associated with the decrease in RF and anti-CCP serum levels that was detected after 24 weeks and remained stable until the 48th week of treatment. Antinuclear and anti-dsDNA autoantibodies, but not anti-phospholipid autoantibodies, can be induced by adalimumab but to a lower extent than in studies with other anti-TNF blocking agents.

引用

页数：8

共 52 条

[11]

BURMESTER GR, 2004, ANN RHEUM DIS, pS63

[12] Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment [J].